The Respiratory Syncytial Virus (RSV) Consortium in Europe, or RESCEU [1] systematically investigates one of the least controlled and rapidly transmitting viral infectious agents in infants. Since 2016, the European Union, through its Innovative Medicines Initiative, has funded this public-private partnership, a consortium of multidisciplinary researchers, industry, government regulators and policy-makers, and community representatives. Working in a transparent and coherent manner, they systematically review the impact of RSV on disease and its economic consequences to demonstrate the societal value for its prevention/control. This Supplement [2] highlights progress in epidemiology, economic valuation, biomedical research, public health strategies, diagnostic biomarkers, therapeutics, and vaccine strategies toward those goals.

中文翻译：

---

建立呼吸道合胞病毒（RSV）控制的价值和策略：欧洲RSV联盟（RESCEU）

欧洲的呼吸道合胞病毒（RSV）联盟或RESCEU [1]系统地研究了婴儿中受控制最少，传播速度最快的病毒感染因子之一。自2016年以来，欧盟通过其“创新药物倡议”为这一公私合作伙伴关系，一个由多学科研究人员，行业，政府监管机构和政策制定者以及社区代表组成的财团提供了资金。他们以透明一致的方式工作，系统地审查了RSV对疾病的影响及其经济后果，以证明其预防/控制的社会价值。本增刊[2]强调了在实现这些目标方面的流行病学，经济价值评估，生物医学研究，公共卫生策略，诊断性生物标志物，疗法和疫苗策略的进展。